Cobalis Board of Directors Commits to Return to Fully Reporting Status and Retains Services of Silberstein Ungar, PLLC

* Reuters is not responsible for the content in this press release.

Tue Apr 6, 2010 9:15am EDT 

  IRVINE, CA, Apr 06 (MARKET WIRE) -- 
In anticipation of a positive confirmation of Cobalis Corporations'
(PINKSHEETS: CLSC) plan for emergence from its bankruptcy, the Board of
Directors of the Company has committed to return to fully reporting
status as quickly as possible, to increase investor confidence and in
preparation for having the Company's stock once again traded on the
NASDAQ OTC BB.

    The Company is pleased to announce that it has retained the services of
Michigan-based accounting firm Silberstein Ungar, PLLC, a nationally
recognized public accounting and audit firm to assist in preparing the
Company's return to fully reporting status.

    In addition, the Company has re-engaged former Chief Financial Officer
Kevin Pickard as Interim CFO to assist in the Company's financial
management.

    Chas Radovich, Cobalis CEO, said: "Cobalis has always been committed to
providing the investment marketplace and institutional investors with
accurate and timely information about the Company's financial status,
future plans, and investment requirements, as well as to report major
news and events on a timely basis. We believe that a return to fully
reporting status and trading on the NASDAQ OTC BB is an urgent
requirement and we are committed to moving quickly to achieve this
milestone as we move forward to bring PreHistin to market nationally and
internationally. The Company appreciates the patience its shareholders
have shown during the recent period, and we are optimistic that good
corporate governance, transparency of disclosures, the addition of highly
experienced management and marketing professionals, and the timely
release of news and information will result in a continually higher level
of investor confidence."

    ABOUT COBALIS CORP -- PREHISTIN(R)

    Cobalis Corp. is an over the counter pharmaceutical and nutraceutical
development company. Its flagship product, "PreHistin(R), The World's
FIRST Pre-Histamine"(TM), is designed to mitigate overproduction of IgE
levels, to restore normal response to seasonal and year-round indoor and
outdoor allergens and reduce the likelihood of onset of allergy symptoms
resulting from histamine release. PreHistin(R) is available without
prescription for both long-term and daily use.

    For PreHistin(R) product information and ordering please visit at
http://www.prehistin.com/ or call toll free 1-877-4POLLEN. For additional
company information please visit their website at http://www.cobalis.com/.

    

CONTACT:

Cobalis Corporation
2030 Main St., Suite 1300
Irvine, CA 92614
949-260-9007

Chas Radovich
Email Contact 
Email Contact 

Copyright 2010, Market Wire, All rights reserved.

-0-
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.